Osteoblastoma and Osteoid Osteoma

Aims:The aim of this study is to evaluate the clinical efficacy of computed tomography (CT)-guided radiofrequency (RF) ablation as a minimally invasive therapy for osteoid osteoma.Materials and Methods:This is a retrospective analysis of prospectively maintained data of 43 symptomatic osteoid osteoma patients who were treated by radiofrequency ablation (RFA). Forty out of 43 patients were naive cases and underwent primary treatment for osteoid osteoma with RFA, whereas 3 patients included in the study underwent RFA for local recurrence after having undergone surgical treatment. Diagnosis was based on clinical and characteristic imaging findings, and biopsy was done for cases with atypical presentation. Pre and post procedure Visual Analog Score (VAS) was documented in all cases. Monopolar RFA system was used in all patients, and the electrode was placed within the lesion nidus under CT guidance coaxially through 11G introducer needle. Ablation was performed at 90° C for 5 min.Results:Technical success rate of intranidal placement of electrode was 100%. The primary clinical success in our study was 97.7% (42 of 43), and the secondary clinical success was 100%. Pre and postprocedure VAS score in our study group was 7.8 and 0.4, respectively. Mean follow-up period in our study was 48 months (Range: 4–129 months). One patient had recurrence of pain 4 years after treatment and was treated successfully by a second session. Minor complications were seen in 3 patients with two cases of RF pad burns and one case of skin burn at the treatment site, and these were managed conservatively. No patients developed temporary/permanent neurological deficits, and no procedure-related mortality was seen in our study.Conclusion:CT-guided percutaneous RFA is a simple, safe, minimally invasive, and highly effective treatment option for osteoid osteoma with good long-term pain control and potentially low disease recurrence.

show abstract

“…The nidus exhibits avid glucose metabolism [ Figure 1D ], whereas surrounding sclerosis does not. [ 13 14 ]…”

Section: Discussionmentioning

confidence: 99%

CT-guided radiofrequency ablation in osteoid osteoma: Result from a tertiary cancer centre in India

Kulkarni

Shetty

Polnaya

et al. 2017

Indian Journal of Radiology and Imaging

View full text Add to dashboard Cite

show abstract

“…But this modality requires more research work to be done to prove its utility in diagnosis and follow up. 30-33 …”

Section: Imaging Findingsmentioning

confidence: 99%

Osteoid osteoma: Contemporary management

Noordin¹,

Allana²,

Hilal³

et al. 2018

Orthop Rev (Pavia)

125

View full text Add to dashboard Cite

Osteoid osteoma is a benign bone-forming tumor with hallmark of tumor cells directly forming mature bone. Osteoid osteoma accounts for around 5% of all bone tumors and 11% of benign bone tumors with a male predilection. It occurs predominantly in long bones of the appendicular skeleton. According to Musculoskeletal Tumor Society staging system for benign tumors, osteoid osteoma is a stage-2 lesion. It is classified based on location as cortical, cancellous, or subperiosteal. Nocturnal pain is the most common symptom that usually responds to salicyclates and non-steroidal anti-inflammatory medications. CT is the modality of choice not only for diagnosis but also for specifying location of the lesion, i.e. cortical vs sub periosteal or medullary. Non-operative treatment can be considered as an option since the natural history of osteoid osteoma is that of spontaneous healing. Surgical treatment is an option for patients with severe pain and those not responding to NSAIDs. Available surgical procedures include radiofrequency (RF) ablation, CT-guided percutaneous excision and en bloc resection.

show abstract

“…Three cases of OO with FDG uptake were found, FDG uptake was about SUV max 4–9. 10 , 11 In this case, SUV max was as high as 12, but there was no report showing stronger FDG accumulation than this case. It currently remains unclear, which cells are responsible for FDG uptake in OO since autoradiography studies have not yet been performed.…”

Section: Discussionmentioning

confidence: 54%

Osteoid osteoma of the rib with strong F-18 fluoro-deoxyglucose uptake mimicking osteoblastoma: a case report with literature review

Ishikura

Yoshida

Yoshizako

et al. 2021

Acta Radiologica Open

View full text Add to dashboard Cite

Osteoid osteoma is a benign osteoblastic bone lesion, characterized by nocturnal pain alleviated by salicylates or nonsteroidal anti-inflammatory drugs. This tumor distinctly affects the long bones, typically the femur or tibia and is rarely located in the ribs. Usually, this tumor is usually diagnosed by computed tomography or magnetic resonance imaging, but F-18 fluoro-deoxyglucose positron emission tomographic (FDG-PET)/computed tomography is usually negative and is not used for diagnosis. We recently encountered a case of an osteoid osteoma located in the rib of 44-year-old Asian male with strong FDG uptake as high as 12.0 at the maximum standardized uptake value at FDG-PET/computed tomography. His computed tomography and magnetic resonance imaging showed osteosclerosis, bone marrow edema, and edema of surrounding tissues not only in the bone with nidus but also in the adjacent bone, and pathological findings showed strong infiltration munched radiology. Strong FDG uptake mimicking osteoblastoma. Osteoid osteoma with strong FDG uptake suggested a strong inflammatory response.

show abstract

Osteoblastoma and Osteoid Osteoma

Cited by 35 publications

References 8 publications

CT-guided radiofrequency ablation in osteoid osteoma: Result from a tertiary cancer centre in India

CT-guided radiofrequency ablation in osteoid osteoma: Result from a tertiary cancer centre in India

Osteoid osteoma: Contemporary management

Osteoid osteoma of the rib with strong F-18 fluoro-deoxyglucose uptake mimicking osteoblastoma: a case report with literature review

Contact Info

Product

Resources

About